SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea · Delayed Price · Currency is KRW 75,800
-900 (-1.17%)
Oct 2, 2026, 3:30 PM KST
SK Biopharmaceuticals Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5,936,144 | 9,757,831 | 8,700,602 | 7,862,650 | 5,646,385 | 7,612,048 | |
Market Cap Growth | -26.55% | 12.15% | 10.66% | 39.25% | -25.82% | -42.48% |
Enterprise Value | 5,603,098 | 9,567,696 | 8,637,734 | 7,807,605 | 5,442,304 | 7,267,516 |
Last Close Price | 75800.00 | 124600.00 | 111100.00 | 100400.00 | 72100.00 | 97200.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 14.80 | 36.55 | 36.14 | - | - | 117.39 |
Forward PE | 16.07 | 39.32 | 73.81 | - | - | - |
PS Ratio | 6.89 | 13.81 | 15.89 | 22.16 | 22.94 | 18.18 |
PB Ratio | 5.81 | 11.81 | 15.16 | 24.50 | 17.84 | 17.14 |
P/TBV Ratio | 5.92 | 12.11 | 16.24 | 29.59 | 18.86 | 17.90 |
P/FCF Ratio | 24.67 | 57.59 | 93.05 | - | - | - |
P/OCF Ratio | 23.89 | 55.34 | 91.68 | - | - | - |
PEG Ratio | 0.83 | 4.68 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 6.51 | 13.54 | 15.77 | 22.00 | 22.11 | 17.36 |
EV/EBITDA Ratio | 19.16 | 43.32 | 75.93 | - | - | 68.18 |
EV/EBIT Ratio | 20.26 | 46.92 | 89.66 | - | - | 76.53 |
EV/FCF Ratio | 23.28 | 56.47 | 92.38 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.05 | 0.06 | 0.32 | 0.56 | 0.49 | 0.04 |
Debt / EBITDA Ratio | 0.15 | 0.22 | 1.62 | - | - | 0.15 |
Debt / FCF Ratio | 0.20 | 0.29 | 1.97 | - | - | - |
Net Debt / Equity Ratio | -0.33 | -0.31 | -0.24 | -0.20 | -0.47 | -0.72 |
Net Debt / EBITDA Ratio | -1.04 | -1.18 | -1.23 | 2.84 | 1.27 | -2.99 |
Net Debt / FCF Ratio | -1.38 | -1.54 | -1.50 | 0.65 | 0.91 | 3.28 |
Asset Turnover | 0.73 | 0.63 | 0.62 | 0.51 | 0.38 | 0.73 |
Inventory Turnover | 0.51 | 0.41 | 0.40 | 0.35 | 0.53 | 0.60 |
Quick Ratio | 2.15 | 1.83 | 1.26 | 1.47 | 2.28 | 2.64 |
Current Ratio | 2.72 | 2.31 | 1.64 | 2.02 | 2.99 | 3.18 |
Return on Equity (ROE) | 47.91% | 36.17% | 50.72% | -11.10% | -36.66% | 15.75% |
Return on Assets (ROA) | 15.98% | 11.40% | 6.84% | -3.38% | -12.53% | 10.38% |
Return on Invested Capital (ROIC) | 44.59% | 40.80% | 27.85% | -17.66% | -89.60% | 127.86% |
Return on Capital Employed (ROCE) | 27.70% | 22.60% | 15.00% | -7.80% | -26.20% | 19.20% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.75% | 2.74% | 2.77% | -0.42% | -2.47% | 0.85% |
FCF Yield | 4.05% | 1.74% | 1.07% | -1.23% | -2.92% | -1.28% |
Buyback Yield / Dilution | - | - | - | - | - | -9.12% |